Report: Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis TOC

1. Executive Summary

2. About Cancer Highlights

3. Methodologies

4. Table of Contents

4.1 List of Figures
4.2 List of Tables

5. How to Use this Report

6. Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Targets

7. The Cancer Genome Project and Prostate Cancer Targets

7.1 Prostate Cancer Targets Present in the Cancer Gene Census and in the Catalogue Somatic Mutations in Cancer

8. Expression Levels of Identified Drug Targets in Prostate Cancer Tissue

9. Pathway Analysis of Prostate Cancer Drugs

10. Target-Target Interactions among Identified Prostate Cancer Targets

11. Structure-based Drug Design in Prostate Cancer is Stimulated by Available

Data on Biological Targets

12. Drug Target Profiles of Prostate Cancer Drugs

12.1.1 Acid Phosphatase Activity Targets
12.1.2 Carboxy-Lyase Activity Targets
12.1.3 Carboxypeptidase Activity Targets
12.1.4 Catalytic Activity Targets
12.1.5 Cell Adhesion Molecule Activity Targets
12.1.6 Chaperone Activity Targets
12.1.7 Chemokine Activity Targets
12.1.8 Complement Activity Targets
12.1.9 Cysteine-Type Peptidase Activity Targets
12.1.10 Cytokine Activity Targets
12.1.11 DNA Repair Protein Targets
12.1.12 DNA Topoisomerase Activity Targets
12.1.13 DNA-Directed DNA Polymerase Activity Targets
12.1.14 G-Protein Coupled Receptor Activity Targets
12.1.15 Growth Factor Activity Targets
12.1.16 Hydrolase Activity Targets
12.1.17 Kinase Activity Targets
12.1.18 Ligand-Dependent Nuclear Receptor Activity Targets
12.1.19 Ligase Activity Targets
12.1.20 Lipid Kinase Activity Targets
12.1.21 Lipid Phosphatase Activity Targets
12.1.22 Metallopeptidase Activity Targets
12.1.23 Molecular Function Unknown Targets
12.1.24 Motor Activity Targets
12.1.25 Oxidoreductase Activity Targets
12.1.26 Peptide Hormone Targets
12.1.27 Protein Binding Targets
12.1.28 Protein Serine/Threonine Kinase Activity Targets
12.1.29 Protein-Tyrosine Kinase Activity Targets
12.1.30 Receptor Activity Targets
12.1.31 Receptor Binding Targets
12.1.32 Receptor Signaling Complex Scaffold Activity Targets
12.1.33 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
12.1.34 RNA Binding Targets
12.1.35 RNA-Directed DNA Polymerase Activity Targets
12.1.36 Serine-Type Peptidase Activity Targets
12.1.37 Structural Constituent of Cytoskeleton Targets
12.1.38 Structural Molecule Activity Targets
12.1.39 Superoxide Dismutase Activity Targets
12.1.40 T Cell Receptor Activity Targets
12.1.41 Transcription Factor Activity Targets
12.1.42 Transcription Regulator Activity Targets
12.1.43 Translation Regulator Activity Targets
12.1.44 Transmembrane Receptor Activity Targets
12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
12.1.46 Transporter Activity Targets

13. The Drug-Target Interactome

14. The Progression and Maturity of Prostate Cancer Targets

14.1 Target Profiles of Prostate Cancer Drugs in Pre-Registration or on the Market
14.2 New and Unique Prostate Cancer Targets in Phase III Clinical Development
14.3 New and Unique Prostate Cancer Targets in Phase II Clinical Development
14.4 New and Unique Prostate Cancer Targets in Phase I Clinical Development
14.5 New and Unique Prostate Cancer Targets in Preclinical Development
14.6 Development Profiles of All Prostate Cancer Target Combinations

15. Targets by R&D Approach in Prostate Cancer

15.1 Small Molecules
- 15.1.1 Background
- 15.1.2 Targets in Prostate Cancer
15.2 Peptide/Protein Drugs
- 15.2.1 Background
- 15.2.2 Targets in Prostate Cancer
15.3 Monoclonal Antibodies and Antibody-Like Structures
- 15.3.1 Background
- 15.3.2 Targets in Prostate Cancer
15.4 Nucleic Acid Therapies
- 15.4.1 Background
- 15.4.2 Targets in Prostate Cancer
15.5 Cell and Gene Therapy
- 15.5.1 Background
- 15.5.2 Targets in Prostate Cancer
15.6 Drug Delivery and Nanotechnology
- 15.6.1 Background
- 15.6.2 Targets in Prostate Cancer

16. Prostate Cancer Targets by Companies

16.1 Australia
16.2 Canada
16.3 Denmark
16.4 Finland
16.5 France
16.6 Germany
16.7 India
16.8 Ireland
16.9 Israel
16.10 Italy
16.11 Japan
16.12 Netherlands
16.13 Norway
16.14 Spain
16.15 Sweden
16.16 Switzerland
16.17 United Kingdom
16.18 USA
16.19 Non-Industrial Bodies

17. Drug Index

18. Company Index

List of Figures

Figure 1: Distribution of Compound Types among Prostate Cancer Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
Figure 4: The Drug-Protein Interactome of Prostate Cancer Drugs - Main Clusters
Figure 5: The Drug-Protein Interactome of Prostate Cancer Drugs - Smaller Clusters
Figure 6: Head-to-Head Targeting Interactome of Prostate Cancer Drugs
4.2 List of Tables
Table 1: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets
Table 2: Drug Targets of Prostate Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer the Cancer Gene Census
Table 3: Expression Levels of Identified Drug Targets in Prostate Cancer Tissue
Table 4: Pathway Summary
Table 5: Drug Targets without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
Table 7: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
Table 8: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
Table 9: Target-Target Interactions among Prostate Cancer Drug Targets
Table 10: Identity of Prostate Cancer Drug Targets with Available Biological Structures
Table 11: Overview of Drug Target Profile Themes
Table 12: Drug-Protein Interactome Clusters
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
Table 14: Top 5 Competitive Prostate Cancer Targets
Table 15: Target Profiles of Prostate Cancer Drugs in Pre-Registration or on the Market
Table 16: New and Unique Prostate Cancer Targets in Phase III Clinical Development
Table 17: New and Unique Prostate Cancer Targets in Phase II Clinical Development
Table 18 New and Unique Prostate Cancer Targets in Phase I Clinical Development
Table 19: New and Unique Prostate Cancer Targets in Preclinical Development
Table 20: The Progression, Maturity and Competitive Comparison of Prostate Cancer Drug Targets in Development
Table 21: Number of Prostate Cancer Drug Target Mixes Reported by Line of Therapy
Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Prostate Cancer Drug Target
Table 23: Drug Targets of Small Molecule Drugs in Prostate Cancer
Table 24: Mechanistic Relationship between Small Molecule Drugs in Prostate Cancer
Table 25: Drug Targets of Peptide Based Drugs in Prostate Cancer
Table 26: Drug Targets of Protein Based Drugs in Prostate Cancer
Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Prostate Cancer
Table 28: Drug Targets of Nucleic Acid Therapies in Prostate Cancer
Table 29: Potential Forms of Cell Therapy
Table 30: Vectors in Gene Therapy
Table 31: Drug Targets of Cell Therapies in Prostate Cancer
Table 32: Drug Targets of Gene Therapies in Prostate Cancer
Table 33: Drug Targets with New Drug Delivery Strategies in Prostate Cancer
Table 34: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Australia
Table 35: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Canada
Table 36: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Denmark
Table 37: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Finland
Table 38: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in France
Table 39: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Germany
Table 40: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in India
Table 41: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Ireland
Table 42: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Israel
Table 43: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Italy
Table 44: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Japan
Table 45: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Netherlands
Table 46: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Norway
Table 47: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Spain
Table 48: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
Table 49: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Switzerland
Table 50: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in United Kingdom
Table 51: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in USA
Table 52: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Non-Industrial Bodies